Cited by 213Bone Metabolism and DiseasesBone health and osteoporosis researchOsteomyelitis and Bone Disorders Research

RANKL/OPG; Critical role in bone physiology

Martin, T. John, Sims, Natalie A.·2015·Reviews in Endocrine and Metabolic Disorders

Abstract

After it was proposed that the osteoblast lineage controlled the formation of osteoclasts, cell culture methods were developed that established this to be the case. Evidence was obtained that cytokines and hormones that promote osteoclast formation act first on osteoblast lineage cells to promote the production of a membrane-bound regulator of osteoclastogenesis. This proved to be receptor activator of NF-kB ligand (RANKL) a member of the tumor necrosis factor ligand family that acts upon its receptor RANK in the hematopoietic lineage, with interaction restricted by a decoy soluble receptor osteoprotegerin (OPG), also a product of the osteoblast lineage. The physiological roles of these factors were established through genetic and pharmacological studies, have led to a new physiology of bone, with complete revision of older ideas over the last 15 years, ultimately leading to the development of new pharmaceutical agents for bone disease.

Integrity signals

Registry

Crossref · 10.1007/s11154-014-9308-6

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Martin, T. J., & Sims, N. A.
Affiliations
The University of Melbourne (AU)
Corresponding author
Martin, T. John
Venue
Reviews in Endocrine and Metabolic Disorders
Published
2015-01-04
Volume
16
Issue
2
Pages
131-139
ISSN
  • 1389-9155 (ISSN-L)
  • 1573-2606
OpenAlex
W1999943656
Cited by
213
References
88
Citations by year
2026: 15 · 2025: 14 · 2024: 18 · 2023: 19 · 2022: 12 · 2021: 23 · 2020: 29 · 2019: 25 · 2018: 21 · 2017: 26 · 2016: 9 · 2015: 2
FWCI
1.87
Type
journal article
Language
en
Open access
closed
Locations
  • Reviews in Endocrine and Metabolic Disorders (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Health and Medical Research Council
  • National Medical Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
Keywords
RANKL, osteoprotegerin, RANK, osteoclastogenesis, osteoblast lineage, bone physiology, bone remodeling
MeSH terms
Animals, Bone and Bones, Humans, Mutation, Osteoblasts, Signal Transduction, Paracrine Communication, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review